Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients with chronic kidney disease and diabetes. Read more here.
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and ...
Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.
Zacks.com on MSN8h
How to Play NVO Stock After New Drug's Success in Obesity StudyNovo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...
Hosted on MSN11h
What Does the Future Hold for Eli Lilly?GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...
For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback